Persistent immune memory of COVID-19 found in recovered patient T cells
New research published in Nature Immunology show strong T cell responses in patients recovered from COVID-19
New research published in Nature Immunology show strong T cell responses in patients recovered from COVID-19
CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for GAVRETO
New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus
Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections
Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021
Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method
Rapid increase in production of VTM and saline will help boost virus testing
A new prognostic tool developed by an international team led by CTI-Bath paves the way for personalized medicine for cancer patients
Watch this on-demand webinar to learn about the latest approaches in single nucleus transcriptomics and ATAC-Seq
The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses
Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors
FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers
Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus
Atomwise provides rapid and cost-effective compound screening to address pharmaceutical R&D productivity
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays
The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants
The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel
The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials
The collaboration is the first larger scale production run of Apta-1 as a non-GMP material, intended for use in GLP toxicology studies